Evidence map›Paper›PMID 42581062›Full record

ArticleScientific reports2026

Shifting AAV9 tropism by binding moiety insertion enhances transduction of tumor cell lines and human glioblastoma explants.

Claire Rothschild-Gronau, Philipp Borchert, Marco T Radukic, Lucas Haverkamp, Roland Coras, Matthias Simon, Kristian M Müller

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Claire Rothschild-GronauCellular and Molecular Biotechnology, Faculty of Technology, Bielefeld University, 33615, Bielefeld, Germany.
Philipp BorchertCellular and Molecular Biotechnology, Faculty of Technology, Bielefeld University, 33615, Bielefeld, Germany.
Marco T RadukicCellular and Molecular Biotechnology, Faculty of Technology, Bielefeld University, 33615, Bielefeld, Germany.
Lucas HaverkampCellular and Molecular Biotechnology, Faculty of Technology, Bielefeld University, 33615, Bielefeld, Germany.
Roland CorasInstitute of Neuropathology, University Hospitals Erlangen, 91054, Erlangen, Germany.
Matthias SimonDepartment of Neurosurgery, Bethel Clinic, University of Bielefeld Medical Center OWL, 33617, Bielefeld, Germany.
Kristian M MüllerCellular and Molecular Biotechnology, Faculty of Technology, Bielefeld University, 33615, Bielefeld, Germany. kristian@syntbio.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor-specific targeting remains a major obstacle for the development of precision cancer therapies. For several tumors and specifically glioblastoma (GBM), an aggressive brain tumor with poor prognosis, more effective treatments are urgently needed. Recombinant adeno-associated viruses (rAAVs), with their established clinical utility and mutational capsid plasticity, offer a promising platform for targeted delivery. We engineered and evaluated modified AAV capsids derived from the established AAV2 with HSPG-tropism knockdown and two less-characterized, tropism-reduced AAV9 variants. The epidermal growth factor receptor (EGFR), a tumor marker often overexpressed in GBM, was targeted by inserting an affibody (Z

Indexed as

Brain NeoplasmsDependovirusGlioblastomaTransduction, GeneticViral TropismCapsidCell Line, TumorErbB ReceptorsGenetic VectorsHumansScorpion VenomsChlorotoxinErbB ReceptorsScorpion VenomsCapsid modificationGlioblastomaRecombinant adeno-associated virusRedirectionTropism knock-out

Identifiers

PMID42581062
PMCPMC13462111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.